{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:52:04Z","timestamp":1790790724054,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T00:00:00Z","timestamp":1505260800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s10067-017-3823-2","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T09:20:11Z","timestamp":1505294411000},"page":"2859-2867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3758-4946","authenticated-orcid":false,"given":"Maria Izabel","family":"de Holanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Crist\u00f3v\u00e3o","family":"P\u00f4rto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Fernando","family":"Christiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian M. P.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,13]]},"reference":[{"issue":"8","key":"3823_CR1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1681\/ASN.V481499","volume":"4","author":"GB Appel","year":"1994","unstructured":"Appel GB, Pirani CL, D'Agati V (1994) Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 4(8):1499\u20131515","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3823_CR2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0272-6386(12)80885-7","volume":"18","author":"G Banfi","year":"1991","unstructured":"Banfi G, Bertani T, Boeri V et al (1991) Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 18(2):240\u2013248","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3823_CR3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0046-8177(85)80212-4","volume":"16","author":"T Tsumagari","year":"1985","unstructured":"Tsumagari T, Fukumoto S, Kinjo M, Tanaka K (1985) Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus. Hum Pathol 16(1):43\u201349","journal-title":"Hum Pathol"},{"issue":"14","key":"3823_CR4","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1177\/0961203310376523","volume":"19","author":"WX Hu","year":"2010","unstructured":"Hu WX, Liu ZZ, Chen HP, Zhang HT, Li LS, Liu ZH (2010) Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy. Lupus 19(14):1591\u20131598","journal-title":"Lupus"},{"key":"3823_CR5","doi-asserted-by":"crossref","first-page":"915309","DOI":"10.1155\/2013\/915309","volume":"2013","author":"GB Vieregge","year":"2013","unstructured":"Vieregge GB, Harrington TJ, Andrews DM, Carpintero MF, Green DF, Nayer A (2013) Catastrophic antiphospholipid syndrome with severe acute thrombotic microangiopathy and hemorrhagic complications. Case Rep Med 2013:915309","journal-title":"Case Rep Med"},{"issue":"6","key":"3823_CR6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","volume":"13","author":"D Erkan","year":"2014","unstructured":"Erkan D, Aguiar CL, Andrade D et al (2014) 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13(6):685\u2013696","journal-title":"Autoimmun Rev"},{"issue":"1","key":"3823_CR7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11926-014-0482-z","volume":"17","author":"I Rodriguez-Pinto","year":"2015","unstructured":"Rodriguez-Pinto I, Espinosa G, Cervera R (2015) Catastrophic APS in the context of other thrombotic microangiopathies. Curr Rheumatol Rep 17(1):482","journal-title":"Curr Rheumatol Rep"},{"key":"3823_CR8","first-page":"704371","volume":"2014","author":"M Strakhan","year":"2014","unstructured":"Strakhan M, Hurtado-Sbordoni M, Galeas N, Bakirhan K, Alexis K, Elrafei T (2014) 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol 2014:704371","journal-title":"Case Rep Hematol"},{"issue":"2","key":"3823_CR9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","volume":"14","author":"BE Lonze","year":"2014","unstructured":"Lonze BE, Zachary AA, Magro CM et al (2014) Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 14(2):459\u2013465","journal-title":"Am J Transplant"},{"issue":"3","key":"3823_CR10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0049-0172(94)90072-8","volume":"24","author":"G Nesher","year":"1994","unstructured":"Nesher G, Hanna VE, Moore TL, Hersh M, Osborn TG (1994) Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 24(3):165\u2013172","journal-title":"Semin Arthritis Rheum"},{"issue":"18","key":"3823_CR11","doi-asserted-by":"crossref","first-page":"e3595","DOI":"10.1097\/MD.0000000000003595","volume":"95","author":"QY Li","year":"2016","unstructured":"Li QY, Yu F, Zhou FD, Zhao MH (2016) Plasmapheresis is associated with better renal outcomes in lupus nephritis patients with thrombotic microangiopathy: a case series study. Medicine (Baltimore) 95(18):e3595","journal-title":"Medicine (Baltimore)"},{"issue":"14","key":"3823_CR12","first-page":"1379","volume":"369","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Loirat C (2013) Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 369(14):1379\u20131380","journal-title":"N Engl J Med"},{"issue":"11","key":"3823_CR13","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","volume":"11","author":"K Hadaya","year":"2011","unstructured":"Hadaya K, Ferrari-Lacraz S, Fumeaux D et al (2011) Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 11(11):2523\u20132527","journal-title":"Am J Transplant"},{"issue":"8","key":"3823_CR14","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","volume":"64","author":"I Shapira","year":"2012","unstructured":"Shapira I, Andrade D, Allen SL, Salmon JE (2012) Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 64(8):2719\u20132723","journal-title":"Arthritis Rheum"},{"issue":"8","key":"3823_CR15","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","volume":"13","author":"G Canaud","year":"2013","unstructured":"Canaud G, Kamar N, Anglicheau D et al (2013) Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 13(8):2179\u20132185","journal-title":"Am J Transplant"},{"issue":"26","key":"3823_CR16","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","volume":"93","author":"A Kronbichler","year":"2014","unstructured":"Kronbichler A, Frank R, Kirschfink M et al (2014) Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 93(26):e143","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3823_CR17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","volume":"30","author":"R Coppo","year":"2015","unstructured":"Coppo R, Peruzzi L, Amore A et al (2015) Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 30(1):167\u2013172","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"3823_CR18","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/TP.0000000000000267","volume":"98","author":"O Bakhtar","year":"2014","unstructured":"Bakhtar O, Thajudeen B, Braunhut BL et al (2014) A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation 98(3):e17\u2013e18","journal-title":"Transplantation"},{"issue":"6","key":"3823_CR19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/RHU.0000000000000290","volume":"21","author":"TA Zikos","year":"2015","unstructured":"Zikos TA, Sokolove J, Ahuja N, Berube C (2015) Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J Clin Rheumatol 21(6):311\u2013313","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"3823_CR20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/rheumatology\/kev371","volume":"55","author":"S Wig","year":"2016","unstructured":"Wig S, Chan M, Thachil J, Bruce I, Barnes T (2016) A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology (Oxford) 55(2):382\u2013384","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3823_CR21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","volume":"65","author":"A El-Husseini","year":"2015","unstructured":"El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP (2015) Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 65(1):127\u2013130","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"3823_CR22","first-page":"2286","volume":"54","author":"MC Pickering","year":"2015","unstructured":"Pickering MC, Ismajli M, Condon MB et al (2015) Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 54(12):2286\u20132288","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"3823_CR23","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.4081\/hr.2016.6625","volume":"8","author":"AG Raufi","year":"2016","unstructured":"Raufi AG, Scott S, Darwish O et al (2016) Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab. Hematol Rep 8(3):6625","journal-title":"Hematol Rep"},{"issue":"6","key":"3823_CR24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/RHU.0000000000000423","volume":"22","author":"RS Bermea","year":"2016","unstructured":"Bermea RS, Sharma N, Cohen K, Liarski VM (2016) Use of eculizumab in atypical hemolytic uremic syndrome, complicating systemic lupus erythematosus. J Clin Rheumatol 22(6):320\u2013323","journal-title":"J Clin Rheumatol"},{"key":"3823_CR25","doi-asserted-by":"crossref","unstructured":"Geethakumari PR, Mille P, Gulati R, Nagalla S. (2017) Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome. Transfus Apher Sci 56(3):400\u2013403","DOI":"10.1016\/j.transci.2017.02.007"},{"issue":"6","key":"3823_CR26","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/ki.1991.155","volume":"39","author":"G Frampton","year":"1991","unstructured":"Frampton G, Hicks J, Cameron JS (1991) Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int 39(6):1225\u20131231","journal-title":"Kidney Int"},{"issue":"5","key":"3823_CR27","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1440-1797.2007.00792.x","volume":"12","author":"B Cheunsuchon","year":"2007","unstructured":"Cheunsuchon B, Rungkaew P, Chawanasuntorapoj R, Pattaragarn A, Parichatikanond P (2007) Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies. Nephrology (Carlton) 12(5):474\u2013480","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"3823_CR28","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/ard.2003.007245","volume":"63","author":"G Espinosa","year":"2004","unstructured":"Espinosa G, Bucciarelli S, Cervera R et al (2004) Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 63(6):730\u2013736","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3823_CR29","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.20433","volume":"50","author":"MG Tektonidou","year":"2004","unstructured":"Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM (2004) Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 50(8):2569\u20132579","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3823_CR30","first-page":"503","volume":"33","author":"G Hernandez-Molina","year":"2015","unstructured":"Hernandez-Molina G, Garcia-Trejo LP, Uribe N, Cabral AR (2015) Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clin Exp Rheumatol 33(4):503\u2013508","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"3823_CR31","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4049\/jimmunol.164.2.786","volume":"164","author":"H Watanabe","year":"2000","unstructured":"Watanabe H, Garnier G, Circolo A et al (2000) Modulation of renal disease in MRL\/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 164(2):786\u2013794","journal-title":"J Immunol"},{"issue":"2","key":"3823_CR32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/01.RES.88.2.245","volume":"88","author":"SS Pierangeli","year":"2001","unstructured":"Pierangeli SS, Espinola RG, Liu X, Harris EN (2001) Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 88(2):245\u2013250","journal-title":"Circ Res"},{"issue":"1","key":"3823_CR33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1681\/ASN.V13142","volume":"13","author":"E Daugas","year":"2002","unstructured":"Daugas E, Nochy D, Huong DL et al (2002) Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 13(1):42\u201352","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3823_CR34","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.V103507","volume":"10","author":"D Nochy","year":"1999","unstructured":"Nochy D, Daugas E, Droz D et al (1999) The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 10(3):507\u2013518","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"3823_CR35","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/acr.22200","volume":"66","author":"N Jordan","year":"2014","unstructured":"Jordan N, Chaib A, Sangle S et al (2014) Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients. Arthritis Care Res (Hoboken) 66(5):725\u2013731","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"3823_CR36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00296-013-2900-3","volume":"34","author":"GL Erre","year":"2014","unstructured":"Erre GL, Bosincu L, Faedda R et al (2014) Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study. Rheumatol Int 34(4):535\u2013541","journal-title":"Rheumatol Int"},{"issue":"1","key":"3823_CR37","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","volume":"15","author":"D Song","year":"2013","unstructured":"Song D, Wu LH, Wang FM et al (2013) The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 15(1):R12","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"3823_CR38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1191\/961203303lu398oa","volume":"12","author":"SS Pierangeli","year":"2003","unstructured":"Pierangeli SS, Harris EN (2003) Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus 12(7):539\u2013545","journal-title":"Lupus"},{"issue":"2","key":"3823_CR39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0961203310395051","volume":"20","author":"R Cervera","year":"2011","unstructured":"Cervera R, Tektonidou MG, Espinosa G et al (2011) Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus 20(2):165\u2013173","journal-title":"Lupus"},{"issue":"8","key":"3823_CR40","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/art.23662","volume":"58","author":"D Cohen","year":"2008","unstructured":"Cohen D, Koopmans M, Kremer Hovinga IC et al (2008) Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum 58(8):2460\u20132469","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3823_CR41","doi-asserted-by":"crossref","first-page":"R206","DOI":"10.1186\/ar3539","volume":"13","author":"A Jonsen","year":"2011","unstructured":"Jonsen A, Nilsson SC, Ahlqvist E et al (2011) Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Res Ther 13(6):R206","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"3823_CR42","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1681\/ASN.2015040385","volume":"27","author":"F Bu","year":"2016","unstructured":"Bu F, Borsa NG, Jones MB et al (2016) High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol 27(4):1245\u20131253","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"3823_CR43","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368(23):2169\u20132181","journal-title":"N Engl J Med"},{"key":"3823_CR44","first-page":"39","volume":"7","author":"LM Palma","year":"2016","unstructured":"Palma LM, Langman CB (2016) Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 7:39\u201372","journal-title":"J Blood Med"},{"issue":"18","key":"3823_CR45","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","volume":"362","author":"BE Lonze","year":"2010","unstructured":"Lonze BE, Singer AL, Montgomery RA (2010) Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 362(18):1744\u20131745","journal-title":"N Engl J Med"},{"issue":"6","key":"3823_CR46","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1046\/j.1523-1755.2001.00730.x","volume":"59","author":"CC Najafi","year":"2001","unstructured":"Najafi CC, Korbet SM, Lewis EJ et al (2001) Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 59(6):2156\u20132163","journal-title":"Kidney Int"},{"issue":"5","key":"3823_CR47","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P et al (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87(5):1061\u20131073","journal-title":"Kidney Int"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3823-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3823-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3823-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T19:52:15Z","timestamp":1659469935000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3823-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,13]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3823"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3823-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,13]]}}}